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Abstract: As articular cartilage is avascular, and mature chon-
drocytes do not proliferate, cartilage lesions have a limited
capacity for regeneration after severe damage. The treatment
of such damage has been challenging due to the limited
availability of autologous healthy cartilage and lengthy and
expensive cell isolation and expansion procedures. Hence,
the use of bone morphogenetic protein-2 (BMP-2), a potent
regulator of chondrogenic expression, has received consider-
able attention in cartilage and osteochondral tissue engineer-
ing. However, the exact role of BMP-2 in cartilage repair has
been postulated to promote both cartilage formation and
subsequent cartilage degradation through hypertrophy and
endochondral ossiﬁcation. Furthermore, it is likely that the
manner in which BMP-2 is presented to chondrocytes will
inﬂuence the physiologic pathway (repair vs. degeneration).
This study investigates the relative inﬂuence of BMP-2 on car-
tilage matrix and potential subsequent bone matrix production
using primary chondrocytes seeded on designed 3D polycap-
rolactone (PCL) scaffolds with chemically conjugated BMP-2.
The results show that chemically conjugated BMP-2 PCL scaf-
folds can promote signiﬁcantly greater cartilage regeneration
from seeded chondrocytes both in vitro and in vivo compared
with untreated scaffolds. Furthermore, our results demonstrate
that the conjugated BMP-2 does not particularly accelerate
endochondral ossiﬁcation even in a readily permissible and
highly vascular in vivo environment compared with untreated
PCL scaffolds. This study not only reveals the potential use of
the BMP-2 conjugation delivery method for enhanced cartilage
tissue formation but also gives new insights for the effects of
conjugated BMP-2 on cartilage regeneration and osteochon-
dral ossiﬁcation. VC 2012 Wiley Periodicals, Inc. J Biomed Mater Res
Part A: 100A: 2088–2096, 2012.
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INTRODUCTION
Degenerative cartilage disease remains a major cause of dis-
ability with over 1 million individuals in the US alone annu-
ally treated for articular cartilage lesions.1 These lesions can
affect the cartilage alone (chondral lesions) or the bone and
cartilage together (osteochondral lesions). Although micro-
fracture, autologous cell implantation (ACI), and osteoarticu-
lar transfer system are widely used therapies to treat these
lesions, they all have signiﬁcant limitations, and thus the
search continues for therapies that can robustly address
chondral and osteochondral lesions.
One widely studied potential therapy is the use of bone
morphogenetic protein-2 (BMP-2). BMP-2 is known to regu-
late and promote proliferation, differentiation, and apoptosis
of various cell lineages in both bone and cartilage develop-
ment and homeostasis.2–6 Recently, van der Kraan et al.7
postulated that bone morphogenetic proteins (BMPs) may
play two contradictory roles (both protective and harmful)
in cartilage development and osteoarthritis development
and progression. For bone and cartilage reconstruction,
BMP-2 is often injected locally and directly8 or delivered
after adsorption on various biomaterials such as collagen
sponges,9,10 hydrogels,10–13 hydroxyapatite,14 and biomate-
rial based microspheres.15,16
Physical adsorption provides limited binding, leading to
bolus delivery that requires high doses to be biologically
effective. The initial burst release characteristic of many
physical adsorption techniques uncontrolled BMP-2
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diffusion into surrounding tissue space and undesired tissue
formation. Previously, our group has successfully introduced
a method of directly attaching BMP-2 to designed, three-
dimensional (3D) polycaprolactone (PCL) scaffolds by a
crosslinking conjugation. Conjugation not only retained
BMP-2 locally in 3D space but also maintained a higher rate
of bioactivity as measured by phosphorylated smad pathway
activation expression compared with physical adsorption.17
Even though BMP-2 has been used extensively to enhance
new bone formation, it is also known to stimulate prechon-
drocyte condensation, and proliferation, matrix production,
and aggrecan synthesis by mature chondrocytes.7,18 The
aim of this study was therefore to evaluate the effect of
chemically conjugated BMP-2 PCL scaffolds on chondrogene-
sis by primary chondrocytes in vitro and in a subcutaneous
in vivo model to determine if controlled BMP-2 delivery is
effective for cartilage regeneration. Furthermore, we wanted
to examine whether BMP-2 could protect formed cartilage
or whether it would accelerate endochondral ossiﬁcation,
the question raised by van de Kraan et al.7 To provide the
most challenging environment to test the chondroprotective
properties of BMP-2, we implanted scaffold/chondrocytes
constructs with or without conjugated BMP-2 into a
vascularized subcutaneous environment after cartilage was
initially formed in vitro (Fig. 1).
RESULTS
Chemically conjugated BMP-2 PCL scaffolds produced and
maintained signiﬁcantly more cartilage matrix quantiﬁed by
the amount of sulfated glycosaminoglycans (sGAG) formed
(1.5 times more) within the BMP-2 conjugated scaffolds
compared with the untreated PCL scaffolds at 4 weeks
in vitro [Fig. 2(B)]. Cells proliferated equally well on both
scaffold groups as there was no signiﬁcant difference in
DNA content after 4 weeks in vitro [Fig. 2(A)]. This implies
that BMP-2 conjugation does not affect the cell proliferation
yet it promotes cartilage matrix formation and retention
within the scaffold pore space in vitro. The mRNA expres-
sion [Fig. 2(C)] measured at 4 weeks in vitro showed that
BMP-2 conjugated PCL scaffolds promoted signiﬁcantly less
de-differentiation indicated by lower type 1 collagen expres-
sion and also a higher collagen type 2 to collagen type 1
gene expression ratio (col2/col1). The col2/col1 ratio,
known as chondrogenic ‘‘differentiation index,19’’ is indica-
tive of more chondrogenic differentiation for cells seeded on
the BMP-2 conjugated PCL scaffolds.
However, there was signiﬁcantly lower aggrecan expres-
sion and relatively higher matrix metalloproteinase 13
(MMP-13) expressions for the BMP-2 conjugated group. This
may indicate a trend toward endochondral ossiﬁcation, as
MMP-13 is produced by chondrocytes that are possibly
FIGURE 1. Scaffold design: (A) a digital picture, (B) micro-CT image of a 3D PCL scaffold from the top view (the center slice), (C) 3D isometric
view of scaffold design (.STL ﬁle image), and (D) micro-CT image of a 3D PCL scaffold from the side view. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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degrading collagen and aggrecan in the cartilage matrix. In
spite of the differences in monolayer versus 3D culture condi-
tions and cell sources from different species, Krawczak et al.20
also reported similar results as our study that the expression
of MMP-13 was upregulated in 5- and 8-week in vitro
monolayer cultures of rabbit chondrocytes with direct BMP-2
treatments and suggested that the elevated MMP-13 levels are
due to the modulation of chondrocytes differentiation and loss
of chondrocytes stability.21–23 Furthermore, the signiﬁcantly
higher type 10 collagen expression along with relatively (but
not signiﬁcantly) higher osteopontin expression for the BMP-2
group may also suggest that BMP-2 was accelerating chondro-
cytes maturation leading to endochondral ossiﬁcation. Histo-
logical examination of both groups [Fig. 3(A)] corresponded to
the quantitative cartilage matrix formation data [Fig. 2(B)]
supporting the conjecture that BMP-2 conjugated scaffolds
promoted cartilage matrix within pore spaces. The BMP-2
group had intense Safranin-O (Saf-O) staining within the scaf-
fold pores, indicative of cartilage matrix, in addition to the
presence of round shape lacunae consistent with chondrocytes.
Histomorphometric quantiﬁcation of Saf-O staining demon-
strated that both total staining and straining within the scaf-
fold pores only were higher in the BMP-2 group [Fig. 3(B)].
In vitro results clearly demonstrated that conjugated
BMP-2 increased cartilage matrix production by chondro-
cytes, but also upregulated genes associated with chondro-
cyte hypertrophy and endochondral ossiﬁcation. The ques-
tion is whether the in vitro gene expression results portend
that controlled BMP-2 delivery to chondrocytes will induce
hypertrophy and increased calciﬁed matrix formation
through endochondral ossiﬁcation. This question was rigor-
ously investigated by implanting chondrocytes seeded on
both BMP-2 conjugated PCL and untreated PCL scaffolds for
5 weeks in a highly vascularized subcutaneous environment
after 6 weeks of in vitro culture.
Histological examination after 5 weeks in vivo, after 6
weeks in vitro (11 weeks total) demonstrated signiﬁcantly
enhanced Saf-O staining within the scaffold pores for the
BMP-2 conjugation group compared with the untreated PCL
group [Figs. 3(A) and 4(A): Saf-O/fast green (FG) longitudi-
nal staining]. Furthermore, the presence of chondrocytic
cells with round phenotype was more vivid around the
inner pore areas. It was obvious that cartilage matrix was
better maintained within the center pore space for BMP-2
group where the less nutrients may have been available
[Fig. 4(A): Saf-O/FG white lined box]. Like the in vitro study,
histomorphometry conﬁrmed that both total and the inner
Saf-O stained area (pore space only) for the BMP-2 conju-
gated group were signiﬁcantly higher than nontreated group
[Fig. 4(B)].
FIGURE 2. (A) the amount of DNA was quantiﬁed to observe the cell proliferation from 0 week (1 day) to 4 weeks in vitro. (B) The amount of
sGAG per DNA was quantiﬁed to measure the matrix formation at 4 weeks in vitro. (C) The mRNA expression for cartilage matrix synthesis-
(col2, col1, col2/col1, and aggrecan), cartilage matrix degradation- (MMP13 and MMP3), hypertrophy- (col10), and bone relevant genes (osteo-
pontin and osteocalcin) was quantiﬁed. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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On the outer edged of both scaffold groups’ hematoxylin
and eosin (H&E) images [Fig. 4(A)], the BMP-2 treated
group presented more and darker stained areas, suggesting
areas of both bone and bone marrow [Fig. 4(A): H&E
arrows]. Bone formation was then further characterized
via micro-computed tomography (CT). Micro-CT analysis
(Fig. 5), however, indicated that there was no signiﬁcant dif-
ference in bone formation in terms of total bone volume,
bone mineral content, and tissue mineral content between
untreated PCL versus BMP-2 conjugated group. Further-
more, there was no bone ingrowth within the scaffold, dem-
onstrating that bone was formed only around or outside of
the scaffold.
DISCUSSION
In this article, we describe the effect of 3D scaffold conju-
gated BMP-2 on both in vitro and in vivo cartilage formation
by seeded porcine chondrocytes. We also investigated
whether BMP-2 conjugation would accelerate chondrocyte
hypertrophy and subsequent endochondral ossiﬁcation
when chondrocyte seeded scaffolds were implanted in a
vascularized subcutaneous in vivo environment. The contra-
dictory roles of BMP-2, on one hand protecting against carti-
lage degeneration and on the other hand enhancing chon-
drocyte hypertrophy were recently reviewed by van der
Kraan et al.7 Both our in vitro and in vivo results suggest
that BMP-2 conjugation facilitates cartilage matrix formation
and maintenance particularly within the scaffold spherical
pore space. The enhanced cartilage matrix production
was perhaps related to BMP-2 inhibiting chondrocyte de-
differentiation as indicated by the lower type I collagen
mRNA expression. Unlike the results by Grunder et al.,24
our results did not indicate any enhancement of the expres-
sion of type 2 collagen and aggrecan by BMP-2 which could
be due to the difference in how BMP-2 was exposed to cells
(i.e., direct contact vs. through alginate beads or the simple
addition vs. conjugation of BMP-2). In a gene therapy study,
Kaps et al.5 showed similar results to ours in that BMP-2
transfected primary bovine articular chondrocytes revealed
no alteration in collagen type II gene expression compared
with control chondrocytes.
The histological examination from in vitro to in vivo
clearly supported the postulate of BMP-2 promoting carti-
lage matrix production and efﬁcient retention within the
scaffolds (Figs. 3 and 4) compared with untreated PCL.
However, there was some evidence from the mRNA expres-
sion at 4 weeks in vitro, speciﬁcally increased type 10 colla-
gen and osteopontin mRNA expression, that BMP-2 may
also accelerate chondrocyte hypertrophy, leading to calciﬁed
cartilage being produced at the end stage of endochondral
ossiﬁcation. There was bone formation and bone marrow
in vivo at the scaffold periphery in both groups, an area
where vascularity would be the highest. However, the amount
of bone formed was not signiﬁcantly different between the
BMP-2 conjugated and untreated PCL groups, indicating that
the presence of conjugated BMP-2 did not increase bone
formation. This result demonstrates that increased gene
expression for cartilage hypertrophy and endochondral ossi-
ﬁcation, namely type 10 collagen and osteopontin, did not
translate into increased bone formation in this in vivo
model. This may be due to the prolonged localization and
slow release of our method for conjugating BMP-2 to scaf-
folds, which prevents BMP-2 protein from diffusing into sur-
rounding cell niches in an unbound state to initiate ossiﬁca-
tion.17 During the several stages of ectopic bone formation
possibly derived by BMP, Tsuyama et al.25 reported that the
induced bone marrow cells were not from undifferentiated
mesenchymal cells in situ, but from hematopoietic stem cells
circulating in the peripheral blood. Tsuyama’s hypothesis
is consistent with our results, especially that the highly
FIGURE 3. In vitro Safranin-O/FG histological examination and semiquantitative histomorphometry demonstrated a comprehensive picture of
the protective role of conjugated BMP-2 on chondrogenesis supporting the quantiﬁcation of matrix formation [Fig. 2(B)]. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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vascular environment on the outside of the scaffold may
inﬂuence bone regeneration much more than the conjugated
BMP2.
Overall, although our in vitro gene expression results
suggested the dual protective and degenerative roles of
BMP-2 on cartilage in vitro,7 our matrix production results
in vitro and in vivo suggest that conjugated BMP-2 pro-
moted cartilage formation but not endochondral ossiﬁcation,
even in the highly vascular in vivo microenvironment.
This ﬁnding is especially relevant considering that the
default fate of chondrocytes or chondrogenically pulsed
stem cells is to produce bone in the ectopic model. Oliveira
et al.26,27 noted that chick embryo chondrocytes cultured
for 20 days in vitro produced bone when implanted ectopi-
cally from 1 to 5 months on a chitosan scaffold. Liu et al.28
chondrogenically pulsed human MSC from 4 to 12 weeks in
vitro on PLA scaffolds, and then implanted the constructs
from 12 to 24 weeks ectopically in immune-compromised
mice. They noted that these constructs supported cartilage
formation in vitro, but when implanted subcutaneously the
matrix converted to bone if it had been cultured less than
12 weeks in vitro. They suggested that the more immature
cartilage matrix had produced VEGF in vitro. However, they
did not quantitatively characterized the 3D distribution of
bone versus soft tissue in the scaffolds using micro-CT, only
through representative histology sections. Thus, it was not
possible to discern the relative spatial distribution and
amount of mineralized versus soft tissue. However, relative
to these results it is possible that the BMP2 conjugated scaf-
folds produce a mature and stable enough cartilage matrix
in vitro to maintain cartilage matrix within the scaffold inte-
rior ectopically in vivo.
Although BMP-2 alone clearly enhanced chondrogenesis,
several groups29–32 have proposed that BMP-2 and TGF-
beta1 synergistically and interactively work together for
chondrogenesis such that BMP-2 promotes chondrocytes dif-
ferentiation, whereas TGF-beta1 modulates the chondrocytes
maturation and terminal differentiation led by BMP-2.
Furthermore, Liu et al.33 documented that multiple factors
currently used for chondroinduction (including TGF-b1, IGF-
1, and BMP-2) were present in the supernatant of chondro-
cyte-engineered constructs and all of these factors were
required for initiating chondrogenic differentiation. On the
basis of these studies, it would be interesting to conjugate
both BMP-2 and TGF-beta1 to observe their effects on chon-
drogenesis in vitro and in vivo. Indeed, the method of pre-
senting BMP-2 and other growth factors (i.e., conjugation/
tightly bound vs. freely diffusible) is likely to have a signiﬁ-
cant effect on how these factors inﬂuence cell behavior.
Strictly based on this study, our results suggest that
chemically conjugated BMP-2 enhanced cartilage matrix syn-
thesis in vitro as seen by the increased sGAG formation,
FIGURE 4. In vivo histological examination and histomorphometry ascertained that the protective and promoting role of BMP-2 for chondrogen-
esis continued from in vitro (Saf-O/FG), but also the future snapshot of hypertrophy predicted by mRNA expression [Fig. 2(C)] was also con-
ﬁrmed by the presence of mature bone marrow at the peripheral scaffold region in H&E (arrows) staining for BMP-2 group. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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more intense sGAG staining, and gene expression and this
enhanced chondrogenesis continued in vivo probably due to
the prolonged retention of BMP-2. BMP-2 conjugation also
upregulated genes associated with cartilage hypertrophy
(col 10) and bone turnover formation in vitro (osteopontin),
giving some indication of an increased tendency toward
endochondral ossiﬁcation. However, the calciﬁed cartilage
resulting from in vivo proteins associated with this gene
expression was not found to a signiﬁcantly higher degree
than the control scaffold and it was formed only on the out-
side of the scaffold. Furthermore, the BMP-2 induced carti-
lage was still maintained in the interior pores of the scaffold
in vivo. This would suggest that BMP-2 does not promote
cartilage hypertropy/endochondral ossiﬁcation to the same
extent it promotes cartilage formation. In this case, the bone
formation on the outside of the scaffolds in both groups
was likely due to the highly vascularized environment on
the outside of the scaffold, not particularly due to the pres-
ence of conjugated BMP-2. Even though there are some
studies suggesting that BMP-2 causes more ossiﬁcation,
these conclusions were mainly based on gene expres-
sion,20,34 not on the quantiﬁcation of actual bone matrix for-
mation in vivo. Our study is the ﬁrst to quantitatively mea-
sure both bone and cartilage formation in vitro and in vivo
and compare it to previous gene expression. Our study also
suggests that there is a desired dose of conjugated BMP-2
that would beneﬁt cartilage regeneration without undesired
cartilage calciﬁcation and ossiﬁcation as long as an appro-
priate and chondrogenically favorable microenvironment is
provided (i.e., actual joint defect site instead of highly vascu-
lar ectopic site).
Still, one could postulate that our results do not rule out
the ability of conjugated BMP-2 to promote both cartilage
formation followed by hypertrophy/ossiﬁcation, if the pro-
tein is continuously around for uptake by the chondrocytes.
However, there is only a limited amount of tightly bound
BMP-2 in the conjugation system. This limited amount of
bound BMP-2 may have been taken up by the chondrocytes
to a large degree after 6 weeks in vitro. Thus, there may not
have been a signiﬁcant amount of BMP-2 left to affect the
seeded or host cells more than the control group in vivo
implantation. This postulate could be tested in experiments
where a BMP-2 conjugated group with chondrocytes and a
control group with chondrocytes are implanted subcutane-
ously without any in vitro culture to see if the BMP-2 conju-
gated group makes more bone and has a direct impact on
endochondral ossiﬁcation in vivo.
In conclusion, the tightly bound form of conjugated
BMP-2 deﬁnitely promoted cartilage matrix production with
porcine chondrocytes in an in vitro environment. Further-
more, this enhanced cartilage matrix was protected and
maintained in the scaffold interior in a highly vascular
in vivo environment. Although there was evidence through
gene expression that BMP2 pushed chondrocytes toward
hypertrophy and endochondral ossiﬁcation in vitro, the
resultant in vivo bone matrix formation only occurred on the
scaffold periphery and was not higher than the control group.
Therefore, it may be that BMP-2 must be continuously avail-
able to the chondrocytes (even in a highly vascularized envi-
ronment) to drive more enhanced endochondral ossiﬁcation
after initial enhancement of cartilage matrix production.
MATERIALS AND METHODS
Scaffold preparation
3D cylindrical PCL scaffolds (6.35 mm diameter, 4 mm
height, 1.62 mm spherical pores with 550 lm internecking
pores, 44% porosity, 100% interconnectivity) were designed
using custom Interactive Data LanguageTM programs (IDL;
FIGURE 5. In vivo micro-CT images of bone formation for both groups (A) and the corresponding quantitative data (B) clearly presented that the
bone formation was not necessarily affected by the presence of BMP-2 directly. There was no signiﬁcant difference in endochondral ossiﬁcation
for BMP-2 group compared with untreated PCL group. [Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Research Systems, Inc.) and the designed scaffolds were
manufactured by a laser sintering machine from an .STL ﬁle
(Fig. 1). The chemically conjugated BMP-2-PCL scaffolds
were prepared using the same aminolysis and crosslinking
method described previously.17 All scaffolds in the BMP-2
group were conjugated with 20 lg BMP-2 protein. All the
scaffolds were sterilized in sterile 70% ethanol for 45 min
then brieﬂy rinsed with PBS three times followed by immer-
sion in serum free media before cell seeding.
Cell isolation
For cell isolation, primary porcine chondrocytes were iso-
lated from the full depth of domestic pig joints as previ-
ously described.35 Cartilage slices were extracted aseptically
within 3 h of slaughter. Chondrocytes were isolated using a
solution of 1 mg/mL collagenase II (Sigma, St. Louis, MO)
in Dulbecco’s modiﬁed Eagle medium (DMEM) containing
500 U/mL penicillin and 500 mg/mL streptomycin (P/S),
100 U/mL kanamycin, and 1:500 amphotericin B (Fungi-
zone, Gibco, Carlsbad, CA). The tissue was digested for 5 h
at 37C with gentle agitation. The cell suspension was
ﬁltered through a nylon sieve (70-mm pore size) and the
centrifuged cell pellets were resuspended in basal culture
medium [DMEM, 10% fetal bovine serum (FBS), 1% P/S,
Gibco] supplemented with 50 mg/mL 2-phospho-L-ascorbic
acid (Sigma) and plated onto tissue culture ﬂasks. Cells
were allowed to adhere for 24 h then trypsinized and
used for in vitro culture.
In vitro cell culture and seeding
The isolated primary porcine chondrocytes were seeded
onto scaffolds and cultured in vitro as previously described
with some modiﬁcation.36–38 Cell suspension was added
dropwise on top of the scaffold at a density of 1  106
cells/scaffold in 60 lL culture medium to allow for initial
cell attachment in a 24 ultra-low attachment well plate.
After 30 min, 1.5 mL of chondrogenic media [basal medium
(DMEM, 10% FBS, 1% P/S, Gibco) supplemented with
50 mg/mL 2-phospho-L-ascorbic acid (Sigma), 0.4 mM pro-
line (Sigma), 5 mg/mL insulin (Gibco), and 0.1 mM nones-
sential amino acids (Gibco)] was added to each well and
further cultured for 4 weeks in vitro or precultured 6 weeks
in vitro followed by 5 weeks in vivo in a mouse subcutane-
ous implantation model. Cell culture was maintained in a
water-jacket incubator equilibrated with 5% CO2 at 37C.
An orbital shaker was used for in vitro culture and both
in vitro and in vivo studies followed the previously estab-
lished protocols.37,38 Four to ﬁve scaffolds per group were
implanted in vivo subcutaneously.
In vivo implantation
Samples were cultured in chondrogenic medium for 6
weeks in vitro and cartilage tissue grown scaffolds subse-
quently implanted into immunodeﬁcient mice for 5 weeks
(6- to 8-week-old; N:NIH-bg-nu-xid, Charles River, Wilming-
ton, MA) following previously protocols.35,38 Four dorsal
subcutaneous pockets were created by blunt dissection and
scaffolds from each group were placed in each pouch and in
a different pouch location in each mouse. The animals were
housed in groups with free access to food and water and
scariﬁed after 5 weeks in vivo (total of 11 week culture and
implantation) for evaluation. Before implantation, absence of
mineralized tissue was conﬁrmed via X-ray. After 5 weeks,
implants were removed and processed histologically.
sGAG and DNA quantiﬁcation. The amount of sGAG and
DNA per scaffold [N ¼ 4–5/group at 0 (1 day) and 4 weeks
in vitro] were determined by using a dimethylmethylene blue
(DMMB) assay, Hoechst 33258 dye and a ﬂuorometer,
respectively, as previously described.36–38 At 0 (1 day) and
4 weeks in vitro, scaffolds at each time point were removed
from culture, ﬁnely chopped, and placed immediately into
1 mL of preprepared papain solution [papain (10 units/mg:
Sigma Aldrich #P4762), 1 PBS, 5 mM cysteine HCL, 5 mM
EDTA, pH¼6.0; mixed for 2 h at 37C then ﬁltered] digested
for less than 24 h at 60C. 10 lL of the digested tissue-scaf-
fold solution was mixed with 200 lL of DMMB reagent and
absorbance was read on a plate reader (MultiSkan Spec-
trum, Thermo, Waltham, MA) at 525 nm. A standard curve
was established from chondroitin 6-sulfate from shark
(Sigma, C4384) to compare absorbance for samples.39,40
The total sGAG were normalized by DNA content which was
measured using Hoechst dye 33258 methods (Sigma, #DNA-
QF). Again, 10 lL digested sample was added to 200 lL
preprepared Hoechst solution and read with excitation at
355 nm and emission at 460 nm (Fluoroskan Ascent FL,
Thermo, Waltham, MA) in a 96 well plate. Readings were
compared with standard curves made from calf thymus
DNA (Sigma, #DNA-QF).41
Quantitative polymerase chain reaction (qtPCR). Chon-
drocytic differentiation marker genes (type 2 collagen, type
2/1 collagen ratio and aggrecan), de-differentiation marker
gene (type 1 collagen), terminal differentiation gene (type
10 collagen), matrix degradation indicator genes (matrix
MMP-3, MMP-13), bone formation and bone turnover indica-
tor genes (osteopontin and osteocalcin, respectively) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
expression were determined by qtPCR using a Gene Amp
7700 sequence detection system (Applied Biosystems, Fos-
ter City, CA) for scaffolds (N ¼ 3–4/group) cultured 4
weeks in vitro using previously established protocols.37,42
The quantity of gene expression was calculated with stand-
ard samples and normalized with GAPDH and the already
readymade porcine primers were obtained from Applied
Biosystems.
Histological examination and histomorphometry. Con-
structs (N ¼ 4–5/group) at each time point in vitro and
in vivo were ﬁxed in 10% buffered formalin overnight, dehy-
drated with a series of graded ethanol, and embedded in
parafﬁn. Tissue sections were stained with H&E or Saf-O/FG
counterstaining for scaffolds to assess cell and tissue distri-
bution, cell morphology and sGAG production at the Histol-
ogy Core of the University of Michigan Dental School. The
cross-sectional and longitudinal views of eight to 10 slides
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(two sections/slide) were obtained from the center of each
scaffold.38,42 Histomorphometry and image analysis was
performed on Saf-O stained slides (N ¼ 8–10/group; total
and inner Saf-O stained area only) using ImageJ software.
Micro-CT analysis
The amount of bone for in vivo samples (N ¼ 4–5/group)
was quantiﬁed by a MS-130 high resolution Micro-CT Scan-
ner (GE Medical Systems, Toronto, CAN) with 75 kV, 75 mA,
and an aluminum ﬁlter. The scanned images were recon-
structed and analyzed using Microview software (GE Health-
care) with regions of interest chosen to contain the entire
scaffold.43
Statistical analysis
Data are expressed as mean 6 standard deviation. The statisti-
cal signiﬁcance among different groups or time points was cal-
culated using t-test using SPSS software. Data were taken to
be signiﬁcant when a p-value of 0.05 or less was obtained.
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